CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A

Dr Vijai Singh serves as Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 book chapters, 17 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.

• 1. Advances in CRISPR-Cas systems for human diseasesVijai Singh2. Advances in CRISPR –Cas systems for human bacterial diseaseIndra Mani3. Advances in CRISPR-Cas systems for gut microbiomeIndra Mani4. Recent progress in CRISPR –Cas systems for human viral diseaseVijai Singh5. Recent development in CRISPR –Cas systems for human protozoan diseasesABHISHEKA BANSAL, Utkarsh Gangwar, Himashree Choudhury and Risha Shameem6. Advances in CRISPR –Cas systems for fungal infectionsAjay Kumar I7. Advances in CRISPR-Cas systems based cell and gene therapyAparna Jayachandran and Arpita Poddar8. Advances in CRISPR-Cas systems for epigeneticsMustafeez Mujtaba Babar, Mahnoor Ilyas, Alvina Gul and Jayakumar Rajadas9. Current progress in CRISPR –Cas systems for cancerMustafeez Mujtaba Babar, Hajra Ali, Hunaiza Fatima, Alvina Gul and Jayakumar Rajadas10. Current progress in CRISPR –Cas systems for autoimmune diseasesAjay Kumar I11. Advances in CRISPR –Cas systems for blood disordersDeepak balaji Thimiri govindaraj and Mutsa Monica Takundwa